Skip to main content
. 2024 Jan 9;16:15–22. doi: 10.2147/BCTT.S442707

Figure 2.

Figure 2

(A) Comparisons of serum thyroid-stimulating hormone (TSH) between estrogen receptor negative (ER-, n = 31) and positive (ER+, n = 66) in patients with both primary breast cancer and primary thyroid cancer. (B) Comparisons of serum TSH between progesterone receptor negative (PR-, n = 28) and positive (PR+, n = 69) in in patients with both primary breast cancer and primary thyroid cancer. Data were shown with box plot. *p < 0.05, **p < 0.01.